Abstract:

Compositions comprising a reverse-temperature sensitive hydrogel comprising a biopolymer such as a polysaccharide and a synthetic polymer, and a compound in an amount that reversibly inhibits respiratory enzyme complex I, and methods of using the composition, are provided.
PREVENTATIVE THERAPY FOR POST-TRAUMATIC
OSTEOARTHRITIS

Claim for Priority

This application claims the benefit of priority of U.S. Provisional Patent Application Serial No. 62/207,059, filed August 19, 2015, the disclosure of which is incorporated by reference herein.

Statement of Government Rights

This invention was made with government support under grant W81XWH-1 1-1-0583 awarded by the Department of Defense. The government has certain rights in the invention.

Background

The pain, immobility, and general disability associated with osteoarthritis are familiar to most people who reach old age. Post-traumatic osteoarthritis (PTOA) is a profoundly accelerated form of arthritis associated with traumatic injuries to joint articular surfaces, leading to disease progression well before patients are considered good candidates for joint replacement approaches common to orthopaedic medicine. Because patients are often injured relatively young and there are presently no viable alternatives to joint replacement, patients with PTOA often suffer disability and morbidity comparable to chronic heart disease patients.

Natural methods for treating PTOA include decreasing load and stress on the injured joint or increasing comfort and functionality. For example, weight loss, low impact exercise, and strengthening muscles surrounding the joint may improve PTOA. However, these approaches do not cure or prevent PTOA and may not be fully effective.

Non-steroidal, anti-inflammatory medicines (NSAIDS) are used to decrease pain and inflammation associated with PTOA, although NSAIDs can cause stomach irritation and kidney, liver or heart problems. Moreover, NSAIDs likely do not prevent PTOA. Antioxidants, another class of compounds used to
treat PTOA, stabilize or deactivate reactive oxygen species (ROS) before they attack cells. Nevertheless, there is skepticism about the benefit of antioxidants and there are potentially harmful side effects if anti-oxidants are taken in excess.

Other methods used to treat PTOA include the administration of cortisone and hylamers which act like artificial joint fluid after injection. However, cortisone can cause elevation of heart rate and blood sugar and should not be given too often. In addition, cortisone is not preventative. While corticosteroid injections are anti-inflammatory, the potential benefit or adverse effects of that injection for traumatic injury have not been resolved. Another approach is the use of platelet-rich plasma injections.

Injection of a patient's own platelets leads to release of growth factors and attraction of regenerative cells to the site of injury. This type of injection is not preventative and does not work for all PTOA patients. Moreover, details on dosage, frequency of injection, and other important parameters have yet to be worked out for platelet rich plasma administration. A further type of injection is an amniotic membrane stem cell injection. While this injection is anti-inflammatory, thus providing pain relief, and results in replacement of damaged cells due to release of growth factors, it is not preventative and does not target ROS.

If non-surgical methods are ineffective, surgical methods may be employed to restore the joint after PTOA. The surgery may include cleaning out, reconstructing or replacing the worn out joint surfaces. As with other surgeries, there can be surgical complications, e.g., infection and damage to surrounding structures, blood clots, heart attack, and stroke, and the eventual wearing out or loosening of implants.

**Summary**

The present disclosure provides an injectable composite hydrogel comprising a polysaccharide, e.g., a natural polysaccharide such as hyaluronic acid, hydroxypropylcellulose, karya gum (KG), guar gum (GUG), or gellan gum (GEG), a semi-synthetic polysaccharide or a synthetic polysaccharide, and a synthetic polymer, e.g., F127, whose reverse-thermal properties cause the composite to become firm once injected (preventing leakage from the site of injection such as a joint), and a compound useful to prevent, inhibit or treat...
PTOA. In one embodiment, the compound reversibly inhibits the respiratory enzyme complex I, a key mediator of chondrocyte injury after impact. In one embodiment, the hydrogei comprises an effective amount of amobarbital, e.g., from about 0.25 mM to about 50 mM or about 1.25 mM to about 10 mM, metformin (N,N-dimethylbiguanide) a biguanide derivative, N,N-diethylbiguanide, N,N-dipropylbiguanide, phenformin (Sogame et al., Biopharm. Drug Dispos., 30:476 (2009)), or HL010183 (Koh et al., Bioorg. Med. Chem., 2L2305 (2013)), or adenosine diphosphate ribose or a derivative thereof. In one embodiment, the volume administered is about 0.1 mL to about 15 mL, e.g., about 1 mL to about 10 mL or about 2 mL to about 5 mL.

The combination of materials in the hydrogei offers a practical advantage, for instance, in enabling health care providers to protect articular tissue acutely after injury. Also, the use of compounds that reversibly inhibit the respiratory enzyme complex I to alter articular cartilage provides for chondroprotection after injury and eventual reestablishment of normal activity of the respiratory enzyme complex I.

The disclosure provides an injectable composition comprising a composite reverse-temperature sensitive hydrogei comprising a biopolymer, such as a polysaccharide, and a synthetic polymer, and a compound in an amount that optionally reversibly inhibits respiratory enzyme complex I. In one embodiment, the hydrogei includes about 0.2 wt/vol to about 4 % wt/vol HA. In one embodiment, the polysaccharide comprises hyaluronic acid. In one embodiment, the synthetic polymer comprises a poloxamer, e.g., F127. In one embodiment, the hydrogei includes about 15% wt/vol to about 20% wt/vol F127.

In one embodiment, the compound comprises amobarbital. In one embodiment, the amount of the compound in the hydrogei inhibits mitochondrial dysfunction or chondrocyte energy dysfunction. In one embodiment, the compound scavenges mitochondrial oxidants or prevents their formation, or stimulates glycolytic ATP production. In one embodiment, the hydrogei comprises N-isopropyl acrylamide polymer, ethylhydroxyethylcellulose, poly(ethylene oxide-b-propylene oxide-b-ethylene oxide), poloxamers, PLURONICS® polymers, poly(ethylene glycol)/poly(D,L-lactic acid-co-glycolic acid) block co-polymers, polysaccharides, alginate, polyphosphazines, polyacrylates, TETRONICS™ polymers, or polyethylene oxide-polypolypropylene glycol block
copolymers. In one embodiment, the polysaccharide comprises hyaluronic acid of about or greater than 1.5 M Dalton. In one embodiment, the MW is about 1,600,000 to 3,200,000, or about 1,900,000 to 3,900,000.

In one embodiment, the polysaccharide comprises hydroxypropylcellulose, karya gum (KG), guar gum (GUG), or gellan gum (GEG). In one embodiment, the polysaccharide is present in the hydrogel at about 0.2% (wt/vol) to about 1.0% (wt/vol).

In one embodiment, the composition is a reverse temperature-sensitive hydrogel (one that is non-viscous at "low" temperature, e.g., at or below room temperature, e.g., about 70°F or less. The low initial viscosity allows the hydrogel to coat all the cartilage surfaces through the joint before it sets (i.e., the viscosity increases at temperatures above room temperature, e.g., about 80°F or greater including human body temperature such as about 98°F), which provides for superior retention in the joint and substantially improves the bioavailability of the compound dissolved in the gel. Reverse temperature-sensitive hydrogels, which have initial viscosities of about 100 to about 160 or about 80 to about 200, e.g., about 120 to about 140, Pascal Seconds, may be administered using a 22 to 24 gauge needle, e.g., a 22 gauge needle. In contrast, non-reverse temperature-sensitive hydrogels require large bore needles and do not evenly distribute in the joint due to their high initial viscosity.

Also provided is a method to prevent or inhibit chondrocyte death and improve chondrocyte function after injury in a mammal. The method includes administering an effective amount of the composition to a mammal having the injury. Further provided is a method to prevent or inhibit post-traumatic osteoarthritis in a mammal. The method includes administering an effective amount of the composition a mammal at risk of posttraumatic osteoarthritis. In one embodiment, the composition comprises hyaluronic acid. In one embodiment, the composition comprises FI27. In one embodiment, the composition comprises amobarbital. In one embodiment, the amount administered inhibits mitochondrial dysfunction or chondrocyte energy dysfunction. In one embodiment, the compound administered scavenges mitochondrial oxidants or prevent their formation, in addition to stimulating glycolytic ATP production. In one embodiment, the administration is within 1, 2, 3, 4 or 5 days of the injury. In one embodiment, the mammal has an injured
joint. In one embodiment, the administration is with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 hours of the injury.

**Detailed Description of the Figures**

Figure 1 is a schematic of the electron transport chain. Electrons from donor molecules are transferred through protein complexes. As electrons are transferred, hydrogen ions are pumped across the inner membrane of the mitochondria, and as the hydrogen atoms fall back over the inner membrane, they generate ATP.

Figure 2 is a schematic of reactive oxygen species production.

Figure 3 is a schematic of steps in the progression to post-traumatic osteoarthritis.

Figure 4 shows complex I activity in the presence or absence of amobarbitai.

**Definitions**

"Hydrogel" as used herein means a water insoluble, naturally or chemically-induced cross-linked, three-dimensional network of polymer chains plus water that fills the voids between polymer.

**Cartilage, Electron Transport and PTOA**

Articular cartilage is the smooth, white tissue that covers the ends of bones where they come together to form joints. It allows the bones to glide over each other with very little friction, and acts as a cushion. Injured, inflamed, or damaged cartilage does not heal itself well due to lack of a blood supply, resulting in symptoms such as pain and limited movement leading to joint damage and deformity. Chondrocytes are cells found in cartilage connective tissue they produce and maintain the cartilage matrix. Under normal circumstances, cartilage wears down over time and chondrocytes replace and repair it as needed.

Chondrocytes, like all cells, contain mitochondria. Mitochondria generate ATP through the Electron Transport Chain (ETC) (Figure 1). Sometimes, harmful substances called reactive oxygen species (ROS) (Figure 2) are created through the ATP generation process and are formed by Respiratory Complex I in
the Electron Transport Chain. ROS can act as signaling molecules and signal healthy chondrocytes to undergo apoptosis (cell suicide), depending on the severity and length of exposure, which leads to osteoarthritis.

Osteoarthritis is wearing out of joint surface cartilage over time. Post-traumatic osteoarthritis (PTOA) is wearing out of a joint that has had any kind of physical injury. PTOA is a debilitating consequence of intraarticular fractures. Patient outcomes after intraarticular fractures have not improved significantly in spite of improved surgical techniques. PTOA is relatively common: As of 2006 approximately 12% of the overall prevalence of symptomatic OA was attributable to PTOA of the hip, knee, or ankle. This corresponds to approximately 5.6 million individuals in the United States being affected by PTOA. The corresponding aggregate financial burden specifically of PTOA is $3.06 billion annually, or approximately 0.15% of the total U.S. health care direct cost outlay.

Compositions and Methods to Prevent, Inhibit or Treat PTOA

Inhibiting electron transport and associated oxidant production by chondrocytes after impact injuries associated with PTOA prevents cell death and dysfunction. Accordingly, by muting chondrocyte mitochondrial metabolism acutely after traumatic injury using compounds that inhibit respiratory complex I (and also decrease ROS) that are delivered intra-articularly in a hydrogel vehicle, the treatment is confined to the joint capsule and prevents leaking out of any joint disruptions present. This allows controlled local delivery of an effective pharmaceutical in a manner that minimizes exposure to the rest of the body. For example, amobarbital is a barbiturate derivative used to produce relaxation, sleep, anesthesia, and anticonvulsant effects. It inhibits respiratory complex I, leading to a decrease in ROS. Because the effect of amobarbital in inhibiting mitochondrial electron transport is reversible, unlike rotenone or other more toxic alternatives, transient manipulation of chondrocyte metabolism in this manner can prevent chondrocyte injury and death, as well as subsequent disease, while avoiding toxic insult to the patient due to return of oxidative metabolism.

The present compositions and method are useful to prevent, inhibit or treat PTOA, and may substantially lower or eliminate treatment costs and
morbidities associated with other more invasive approaches that require multiple surgical procedures and/or cell harvests.

Hydrogels and Polymers Useful in Hydrogels

Hydrogels can be classified as those with crosslinked networks having permanent junctions or those with physical networks having transient junctions arising from polymer chain entanglements or physical interactions, e.g., ionic interactions, hydrogen bonds or hydrophobic interactions. Natural materials useful in hydrogels include natural polymers, which are biocompatible, biodegradable, support cellular activities, and may include proteins like fibrin, collagen or gelatin, and/or polysaccharides like hyaluronic acid, starch, alginate or agarose. Synthetic polymers useful in hydrogels are prepared by chemical polymerization and include by way of example poloxamers, acrylic acid, hydroxyethyl-methacrylate (HEMA), vinyl acetate, and methacrylic acid (MAA).

Various methods may be used to prepare hydrogels, e.g., crosslinkers, copolymerization of monomers using multifunctional co-monomer, cross linking of linear polymers by irradiation or by chemical compounds. Monomers contain an ionizable group that can be ionized or can undergo a substitution reaction after the polymerization is completed. Exemplary crosslinkers are glutaraldehyde, calcium chloride and oxidized konjac glucomannan (DAK).

Some classes of hydrogels include (a) homopolymeric hydrogels which are derived from a single species of monomer. Homopolymers may have crosslinked skeletal structure depending on the nature of the monomer and polymerization technique, (b) copolymeric hydrogels which are comprised of two or more different monomer species with at least one hydrophilic component, arranged in a random, block or alternating configuration along the chain of the polymer network; (c) multipolymer interpenetrating polymeric hydrogel (IPN) which is made of two independent cross-linked synthetic and/or natural polymer components, contained in a network form. In semi-IPN hydrogel, one component is a cross-linked polymer and other component is a non-cross-linked polymer.

Biodegradable hydrogels as a delivery vehicle have the advantage of being environmentally friendly to the human body (due to their biodegradability) and of providing more predictable, controlled release of the impregnated daigs.
Hydrogels are of special interest in biological environments since they have a high water content as is found in body tissue and are highly biocompatible. Hydrogels and natural biological gels have hydrodynamic properties similar to that of cells and tissues. Hydrogels minimize mechanical and frictional irritation to the surrounding tissue because of their soft and compliant nature. Therefore, hydrogels provide a far more user-friendly delivery vehicle than the relatively hydrophobic carriers like silicone, or vinyl acetate.

Biocompatible materials that may be present in a hydrogel include, e.g., permeable configurations or morphologies, such as polyvinyl alcohol, polyvinylpyrrolidone and polyacrylamide, polyethylene oxide, poly(2-hydroxyethyl methacrylate); natural polymers such as polysaccharides, gums and starches; and include poly[a(4-aminobutyl)]-l-glycolic acid, polyethylene oxide, polyorthoesters, silk-elastin-like polymers, alginate, EVAc (poly(ethylene-co-vinyl acetate), microspheres such as poly (D, L-lactide-co-glycolide) copolymer and poly (L-lactide), poly(N-isopropylacrylamide)-b-poly(D,L-lactide), a soy matrix such as one cross-linked with glyoxal and reinforced with a bioactive filler, e.g., hydroxypatite, poly(epsilon-caprolactone)-poly(ethylene glycol) copolymers, polyacryloyl hydroxyethyl) starch, polylysine-polyethylene glycol, or agarose.

In one embodiment, the hydrogel includes poloxamers, polyacrylamide, poly(2-hydroxyethyl methacrylate), carboxyvinyl-polymers (e.g., Carbopol 934, Goodrich Chemical Co.), cellulose derivatives, e.g., methyleelulose, cellulose acetate and hydroxypropyl cellulose, polyvinyl pyrrolidone or polyvinyl alcohols, or combinations thereof.

In some embodiments, the hydrogel includes collagen, e.g., hydroxylated collagen, fibrin, polylactic-polyglycolic acid, or a polyanhydride. Other examples include, without limitation, any biocompatible polymer, whether hydrophilic, hydrophobic, or amphiphilic, such as ethylene vinyl acetate copolymer (EVA), polymethyl methacrylate, polyamides, polycarbonates, polyesters, polyethylene, polypropylenes, polystyrenes, polyvinyl chloride, polytetrafluoroethylene, N-isopropylacrylamide copolymers, polyethylene oxide)/poly(propylene oxide) block copolymers, poly(ethylene glycol)/poly(D,L-lactide-co-glycolide) block copolymers, polyglycolide,
polylactides (PLLA or PDLA), poly(caprolactone) (PCL), or poly(dioxanone) (PPS).

In another embodiment, the biocompatible material includes polylethylenereterephaiate, polytetrafluoroethylene, copolymer of polyethylene oxide and polypropylene oxide, a combination of polyglycolic acid and polyhydroxyalkanoate, gelatin, alginate, poly-3-hydroxybutyrate, poly-4-hydroxybutyrate, and polyhydroxyoctanoate, and polycrylonitrilepolyvinylchlorides.

In one embodiment, the following polymers may be employed, e.g., natural polymers such as alginate, agarose, starch, fibrin, collagen, gelatin, chitin, glycosaminoglycans, e.g., hyaluronic acid, dermatan sulfate and chondroitin sulfate, and microbial polyesters, e.g., hydroxyalkanoates such as hydroxyvalerate and hydroxybutyrate copolymers, and synthetic polymers, e.g., poly(orthoesters) and polyanhydrides, and including homo and copolymers of glycolide and lactides (e.g., poly(L-lactide, poly(L-lactide-co-D,L-lactide), poly(L-lactide-co-glycolide, poiyglycolide and poly(D,L-lactide), pol(D,L-lactide-coglycoiide), polyfastic acid colysine) and polycaprolactone.

In one embodiment, the hydrogel comprises a poloxamer (polyoxyethylene, polyoxypropylene block copolymers, e.g., poloxamer 127, 231, 182 or 184).

**Exemplary Components for Use in Hydrogels to Prevent, Inhibit or Treat PTOA**

In one embodiment, the hydrogels useful in the compositions and methods of the invention are synthesized from a naturally occurring biodegradable, biocompatible, and hydrophilic polysaccharide, and a synthetic biocompatible polymer, such as poloxamers, polylactide ("PLA"), poiyglycolide ("PGA"), or poly(lactic acid co-glycolic acid) ("P1,G/V").

The composition of the invention that forms a hydrogel, e.g., a reverse temperature-sensitive hydrogel, includes a polysaccharide, including chemically cross linked polysaccharides and a synthetic or natural polymer, and a compound that reversibly inhibits complex I. One exemplary polysaccharide is hyaluronic acid (HA), a naturally occurring co-polymer composed of the sugars glucuronic acid and N-acetylglucosamine. Specifically, HA, also named hyaluronan, is a high molecular weight (10^4–10^7 Da) naturally occurring biodegradable polymer that is an unbranched non-sulfated glycosaminoglycan (GAG) composed of
repeating disaccharides (β-1,4-D-gluconic acid (known as uronic acid) and β-
1,3-N-acetyl-D-glucosamide). HA has an average MW of 4-5 million Da. HA
can include several thousand sugar molecules in the backbone. HA is a
polyanion that can self-associate and that can also bind to water molecules
(when not bound to other molecules) giving it a stiff, viscous quality similar to
gelatin. Hylans are cross-linked hyaluronan chains in which the carboxylic and
N-acetyl groups are unaffected. The MW of hylan A is about 6 million Da.
Hylans can be water-insoluble as a gel (e.g., hylan B).

HA’s characteristics include its consistency, biocompatibility,
hydrophilicity, viscoelasticity and limited immunogenicity. The hyaluronic acid
backbone is stiffened in physiological solution via a combination of internal
hydrogen bonds, interactions with solvents, and the chemical staucture of the
disaccharide. At very low concentrations, HA chains entangle each other,
leading to a mild viscosity (molecular weight dependent). On the other hand, HA
solutions at higher concentrations have a higher than expected viscosity due to
greater HA chain entanglement that is shear-dependent. Thus, solutions
containing HA are viscous, but the viscosity is tunable by varying HA
concentration and the amount of cross-linking. In addition to the unique
viscosity of HA, the viscoelasticity of HA is another characteristic resulting from
entanglement and self-association of HA random coils in solution.
A viscoelasticity of HA can be tied to molecular interactions which are also
dependent on concentration and molecular weight.

Exemplary HA solutions for injection are shown in Table 1, and include
include Synvisc® (high molecular weight HA due to crosslinking), Hyalgan®
sodium hyaluronate solution), and Orthovisc® (one of the viscosupplements
with the highest HA concentration, which has lower viscosity than Synvisc®)
(the properties of those are shown in Table 2).

<table>
<thead>
<tr>
<th>Brand name (Generic name)</th>
<th>Molecular weight (kDa)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Durolane® (Hyaluronic acid, 2%)</td>
<td>1000</td>
</tr>
<tr>
<td>Fermathron® (Sodium hyaluronate, 1%)</td>
<td>1000</td>
</tr>
<tr>
<td>Hyalgan® (Sodium hyaluronate, 1%)</td>
<td>500-730</td>
</tr>
<tr>
<td>NeoVisc® (Sodram hyaluronate, 1%)</td>
<td>1000</td>
</tr>
<tr>
<td>Orthovisc® (Sodium hyaluronate, 1%)</td>
<td>1000-2900</td>
</tr>
<tr>
<td>Ostenil® (Sodram hyaluronate, 1%)</td>
<td>1000-2000</td>
</tr>
</tbody>
</table>
Dextran is another polysaccharide and is formed primarily of 1,6-a-D-glucopyranosyl residues and has three hydroxyl groups per glucose residue that could provide greater flexibility in the formulation of hydrogels. Dextran has been widely used for many biomedical purposes, such as plasma expander and controlled drug delivery vehicle, because of its highly hydrophilic nature and biocompatibility. It is also possible to incorporate dextranase in order to facilitate biodegradation of dextran for the meeting of specific clinical needs.

In one embodiment, the hydrogel comprises a poloxamer. Poloxamers are nonionic triblock copolymers composed of a central hydrophobic chain of polyoxypropylene (poly(propylene oxide)) flanked by two hydrophilic chains of polyoxyethylene (poly(ethylene oxide)) (OC-Hydro-co-hydroxypoly(oxyethylene)a-poloxamer-poloxylene) block copolymer, with two hydrophilic chains of ethylene oxide chains (PEO) that sandwich one hydrophobic propylene oxide chain (POO) giving a chemical formula $\text{HO(C}_2\text{H}_4\text{O)}_{a}\text{(C}_3\text{H}_6\text{O)}_{i}\text{(C}_2\text{H}_4\text{O})_{b})$. For example, poloxamer 407 is a triblock copolymer consisting of a central hydrophobic block of polypropylene glycol flanked by two hydrophilic blocks of polyethylene glycol. Exemplary poloxamers include but are not limited to polyethylene-propylene glycol copolymer, e.g., Supronic, Plurome or Tetronic a non-ionic triblock copolymer.

The common representation of Poloxamer is indicated as ’P’ succeeded by three digits where the first two digits are to be multiplied by 100 and that gives the molecular mass of the hydrophobic propylene oxide and the last digit is to be multiplied by ten that gives the content of hydrophilic ethylene oxide in

<table>
<thead>
<tr>
<th>Brand name (Generic name)</th>
<th>Molecular weight (kDa)</th>
<th>Table 2 Viscoelastic properties</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hylan G-F® 20; Crosslinked HA</td>
<td>6000-7000</td>
<td>Elastic modulus (G’) (Pa) at 2.5 Hz</td>
</tr>
<tr>
<td>Supartz® (Sodium hyaluronate, 1%)</td>
<td>62.0-1170</td>
<td>Viscous modulus (G”) (Pa) at 2.5 Hz</td>
</tr>
<tr>
<td>Suplasyn® (Sodium hyaluronate, 1%)</td>
<td>500-730</td>
<td>0.6</td>
</tr>
<tr>
<td>Synvisc® (Crosslinked polymer)</td>
<td>111 ± 13</td>
<td>60</td>
</tr>
</tbody>
</table>
percentage. Poloxamers usually have an efficient thermoreversible property with characteristics sol-gel transition temperature. Below the transition temperature it is present as a solution and above this temperature the solution results in interaction of the copolymer segment which leads to gelation.

Poloxamers are non-toxic and non-irritant.

<table>
<thead>
<tr>
<th>Poloxamer</th>
<th>Pluronic</th>
<th>Physical form</th>
<th>Ethylene oxide units (n)²</th>
<th>Propylene oxide units (n)³</th>
<th>Average molecular mass</th>
<th>Weight % of Oxyethylene</th>
</tr>
</thead>
<tbody>
<tr>
<td>124</td>
<td>L-44</td>
<td>Liquid</td>
<td>10-15</td>
<td>18-23</td>
<td>2090-2360</td>
<td>44.8-48.6</td>
</tr>
<tr>
<td>188</td>
<td>F-68</td>
<td>Solid</td>
<td>75-85</td>
<td>25-40</td>
<td>7680-9510</td>
<td>79.9-83.7</td>
</tr>
<tr>
<td>237</td>
<td>F-87</td>
<td>Solid</td>
<td>60-68</td>
<td>35-40</td>
<td>6840-8830</td>
<td>70.5-74.3</td>
</tr>
<tr>
<td>338</td>
<td>F-108</td>
<td>Solid</td>
<td>137-146</td>
<td>42-47</td>
<td>12700-17400</td>
<td>81.4-84.9</td>
</tr>
<tr>
<td>407</td>
<td>F-127</td>
<td>Solid</td>
<td>95-105</td>
<td>54-60</td>
<td>9840-14600</td>
<td>71.5-74.9</td>
</tr>
</tbody>
</table>

Compounds that reversibly inhibit complex I include but are not limited to amobarbital or derivatives thereof, metformin or derivatives thereof, or adenosine diphosphate ribose analogs that disrupt NADH binding. However, non-reversible inhibitors of complex I, e.g., Rotenone, Piericidin A or Roliniastatin 1 and 2, in low doses, may also have some benefit to cartilage after injury as a result of altering ROS.

Formulations and Dosages

The components of the composition of the invention can be formulated as pharmaceutical compositions and administered to a mammalian host, such as a human patient in a variety of forms adapted to the chosen route of administration. In one embodiment, the components of the composition are locally administered to a site of cartilage damage or suspected cartilage damage, or is administered prophylactically.

In one embodiment, the components of the composition may be administered by infusion or injection. Solutions may be prepared in water, optionally mixed with a nontoxic surfactant. Dispersions may also be prepared in glycerol, liquid polyethylene glycols, triacetin, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
The pharmaceutical dosage forms suitable for injection or infusion may include sterile aqueous solutions or dispersions or sterile powders comprising the active ingredient which are adapted for the extemporaneous preparation of sterile injectable or infusible solutions or dispersions. In all cases, the ultimate dosage form should be sterile, fluid and stable under the conditions of manufacture and storage. The liquid carrier or vehicle may be a solvent or liquid dispersion medium comprising, for example, water, ethanol, a polyol (for example, glycerol, propylene glycol, liquid polyethylene glycols, and the like), vegetable oils, nontoxic glyceryl esters, and suitable mixtures thereof. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it may be preferable to include isotonic agents, for example, sugars, buffers or sodium chloride.

Sterile injectable solutions may be prepared by incorporating the active agent in the required amount in the appropriate solvent with various other ingredients, as required, optionally followed by filter sterilization. In the case of sterile powders for the preparation of sterile injectable solutions, the methods of preparation include vacuum drying and the freeze drying techniques, which yield a powder of the active ingredient plus any additional desired ingredient present in the previously sterile-filtered solutions.

Useful solid carriers may include finely divided solids such as talc, clay, microcrystalline cellulose, silica, alumina and the like. Useful liquid carriers include water, alcohols or glycols or water-alcohol/glycol blends, in which the present compounds can be dissolved or dispersed at effective levels, optionally with the aid of non-toxic surfactants. Adjuvants such as antimicrobial agents can be added to optimize the properties for a given use. Thickeners such as synthetic polymers, fatty acids, fatty acid salts and esters, fatty alcohols, modified celluloses or modified mineral materials can also be employed with liquid carriers to form spreadable pastes, gels, ointments, soaps, and the like, for application directly to the skin of the user.

Useful dosages of the compound(s) in the composition can be determined by comparing their in vitro activity and in vivo activity in animal models thereof. Methods for the extrapolation of effective dosages in mice, and other animals, to humans are known to the art; for example, see U.S. Pat. No. 4,938,949.
Generally, the concentration of the compound(s) in a liquid composition, may be from about 0.1-25 wt-%, e.g., from about 0.5-10 wt-%. The concentration in a semi-solid or solid composition such as a gel or a powder may be about 0.1-5 wt-%, e.g., about 0.5-2.5 wt-%.

The amount of the compound for use alone or with other agents may vary with the type of hydrogel, route of administration, the nature of the condition being treated and the age and condition of the patient, and will be ultimately at the discretion of the attendant physician or clinician.

The components of the composition may be conveniently administered in unit dosage form; for example, containing 5 to 1000 mg, conveniently 10 to 750 mg, or conveniently 50 to 500 mg of active ingredient per unit dosage form.

In general, however, a suitable dose may be in the range of from about 0.5 to about 100 mg/kg, e.g., from about 10 to about 75 mg/kg of body weight per day, such as 3 to about 50 mg per kilogram body weight of the recipient per day, for example in the range of 6 to 90 mg/kg/day, e.g., in the range of 15 to 60 mg/kg/day.

The invention will be described by the following non-limiting example.

**Example**

In one embodiment, an injectable temperature-sensitive composite hydrogel is employed where the hydrogel is liquid during injection, then gelates when inside the body (gelates at human body temperatures). In one embodiment, the injectable temperature-sensitive composite hydrogel (e.g., one having hyaluronic acid, such as Gel One which is chemically cross-linked and has a high molecular weight, and F127) is employed to deliver a therapeutic, for instance, the hydrogel is loaded with amobarbital which reversibly inhibits the respiratory enzyme Complex I, a key mediator of chondrocyte injury after impact. The hydrogel becomes firm once injected (preventing leakage from the joint) allowing the therapeutic to be retained in the joint region, for example, for about 3 days after injection into the site of articular injury. In one embodiment, the hydrogel comprises 17% (w/v) F127 and 0.2% (w/v) HA, and is loaded with 2.5 mM amobarbital. The temperature-sensitive hydrogel fixes the amobarbital, which prevents chondrocyte death, at the site of injury.
Figure 4 shows that amobarbital directly inhibits the biochemical activity of complex I of the electron transport chain in chondrocytes.

References

5 Martin et al., Journal of Bone and Joint Surgery, 91A:1890.
Jubeck, Arthritis Rheum., 58(9):2809.

All publications, patents and patent applications are incorporated herein by reference. While in the foregoing specification, this invention has been described in relation to certain preferred embodiments thereof, and many details have been set forth for purposes of illustration, it will be apparent to those skilled in the art that the invention is susceptible to additional embodiments and that certain of the details herein may be varied considerably without departing from the basic principles of the invention.
WHAT IS CLAIMED IS:

1. An injectable composition comprising a reverse-temperature sensitive hydrogel comprising hyaluronic acid, hydroxypropylicelulose, karaya gum (KG), guar gum (GUG), or gellan gum (GEG) and a synthetic polymer, and a compound in an amount that reversibly inhibits respiratory enzyme complex I.

2. The composition of claim 1 wherein the hyaluronic acid hydroxypropylicelulose, karya gum, guar gum, or gellan gum is about or greater than 1.0 M Dalton.

3. The composition of claim 1 or 2 wherein the hyaluronic acid is present in the composition from about 0.01% (wt/vol) and up to about 2.0% (wt/vol).

4. The composition of claim 1 wherein the hyaluronic acid is present at about 0.2% to about 1.0% wt/vol.

5. The composition of any one of claims 1 to 4 wherein the hydrogel comprises N-isopropyl acrylamide polymer, polysaccharides other than hyaluronic acid, hydroxypropylicelulose, karya gum, guar gum, or gellan gum such as alginate or ethyhydroxyethylcellulose, polyethylene oxide-b-propylene oxide-b-ethylene oxide), poloxamers, PLURONICS® polymers, poly(ethylene glycoi)/poly(D,L-lactic acid-co-glycolic acid) block co-polymers, polyphosphazines, polyacrylates, TETRONICS™ polymers, or polyethylene oxide-polypropylene glycol block copolymers.

6. The composition of any one of claims 1 to 5 wherein the compound comprises barbital, adenosine diphosphate ribose, or metformin, or a derivative thereof.

7. The composition of any one of claims 1 to 6 wherein the amount inhibits mitochondrial dysfunction or chondrocyte energy dysfunction.
8. The composition any one of claims 1 to 7 wherein the compound scavenges mitochondrial oxidants or prevents their formation, or stimulates glycolytic ATP production.

9. A method to prevent or inhibit chondrocyte death and improve chondrocyte function after injury in a mammal, comprising locally administering an effective amount of the composition of any one of claims 1 to 8 to an injured joint of a mammal.

10. A method to prevent or inhibit post-traumatic osteoarthritis in a mammal, comprising locally administering an effective amount of the composition of any one of claims 1 to 8 to a mammal at risk of posttraumatic osteoarthritis as a result of injury to cartilage.

11. The method of claim 9 or 10 wherein the composition is injected.

12. The method of any one of claims 9 to 11 wherein the composition comprises hyaluronic acid and a poloxamer.

13. The method of claim 12 wherein the composition comprises F127.

14. The method of any one of claims 9 to 13 wherein the composition comprises amobarbital, pentobarbital, secobarbital, phenobarbital, or metformin or a derivative thereof.

15. The method of any one of claims 9 to 14 wherein the amount inhibits mitochondrial dysfunction or chondrocyte energy dysfunction.

16. The method of any one of claims 9 to 15 wherein the administration reduces ROS production in cartilage.

17. The method of any one of claims 9 to 16 wherein the administration is within 4 days of the injury.
18. The method of claim 10 wherein the mammal has an injured joint.

19. The method of any one of claims 9 to 18 wherein the administration is with 12 hours of the injury.

20. The method of any one of claims 9 to 18 wherein the administration is with 5 hours of the injury.

21. The method of any one of claims 9 to 20 wherein the injury is a knee, hip, ankle or elbow injury.
FIG. 1

INNER MITOCHONDRIAL MEMBRANE

ELECTRON PAIR

ATP SYNTHASE

ADP + P_i

H^+

ELECTRON PAIR, FREE ENERGY

O_2

H^+

H^+

H^+

H^+

Cyt C

Q

II

III

IV

1/4
FIG. 4
INTERNATIONAL SEARCH REPORT

International application No
PCT/US2016/047360

A. CLASSIFICATION OF SUBJECT MATTER

INV. A61L27/26 A61L27/50 A61L27/52 A61L27/54 A61K9/00
A61K9/06 A61K47/34

ADD.

According to International Patent Classification (IPC) or both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A61L A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, WPI Data, BIOSIS, EMBASE, INSPEC

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>Todd 0 Mckinley ET AL: &quot;TITLE: Mi tochondrial Based Treatments that Prevent Post-Traumatic Osteoarthrosis, a Translational Large Animal Intraarticular Fracture Survival Model PRINCIPAL INVESTIGATOR: DISTRIBUTION STATEMENT: Approved for Public Release; Distribution unlimited on Unimidi&quot;.</td>
<td>1-21</td>
</tr>
</tbody>
</table>

X Further documents are listed in the continuation of Box C.

X See patent family annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier application or patent but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another publication or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

*I* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

*X* document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

*Y* document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

*A* document member of the same patent family

Date of the actual completion of the international search

14 November 2016

Date of mailing of the international search report

21/11/2016

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL-2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Cadamuro, Sergi

Form PCT/ISA/210 (second sheet) (April 2005)
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Y</td>
<td>MOHAMMED M MOHAMMED ET AL: &quot;Evaluation of the Clinical use of Metformin or Pioglitazone in Combination with</td>
<td>1-21</td>
</tr>
<tr>
<td></td>
<td>Meloxicam in Patients with Knee Osteoarthritis; Outcome Score&quot;, IRAQI J PHARM SCI,</td>
<td></td>
</tr>
<tr>
<td>Y</td>
<td>EP 1 496 037 Al (CHUGAI PHARMACEUTICAL CO LTD [JP]) 12 January 2005 (2005-01-12)</td>
<td>1-21</td>
</tr>
<tr>
<td></td>
<td>claims 1-6, 9, 11-13 paragraphs [0058], [0060]</td>
<td></td>
</tr>
<tr>
<td>Patent document cited in search report</td>
<td>Publication date</td>
<td>Patent family member(s)</td>
</tr>
<tr>
<td>--------------------------------------</td>
<td>-----------------</td>
<td>--------------------------</td>
</tr>
<tr>
<td>AU 2003235248</td>
<td>27-10-2003</td>
<td>JP 5155513 B2</td>
</tr>
<tr>
<td>TW 200307011 A</td>
<td>01-12-2003</td>
<td>US 2005164980</td>
</tr>
<tr>
<td>WO 03087019 A</td>
<td>23-10-2003</td>
<td></td>
</tr>
</tbody>
</table>